The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

IV therapy is gaining popularity as a lifestyle wellness trend, but experts question its safety and necessity. Learn about ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...

Las Vegas, NV / Syndication Cloud / January 23, 2026 / ContrastConnect The American College of Radiology (ACR) and the ...

Vitality Urgent Care is now open in Lake Zurich, expanding access to walk in medical care for families and residents in Lake ...

A judge has ruled that Tennessee prison officials must grant expanded access to media members to view state-run executions.

Many peptides are produced either by compounding pharmacies in the U.S. or by an ever-growing number of factories in China. The most serious users tend to get peptides from the latter for both a wider ...

ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...

A NASA astronaut on the ISS captured the Space Launch System rocket for Artemis 2, a mission that aims to bring four ...

Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...